HSCT With Omidubicel Achieved Robust Immune Reconstitution and Lower Rates of Severe Infection Compared to UCB Transplantation

Video

Expert hematologist/oncologist Paul Szabolcs, MD, reviews positive data from a clinical trial comparing hematopoietic stem cell transplantation and omidubicel with standard cord blood transplantation.

Paul Szabolcs, MD, discusses data from the following study:

  • Hematopoietic Stem Cell Transplantation (HSCT) With Omidubicel Is Associated With Robust Immune Reconstitution and Lower Rates of Severe Infection Compared to Standard Umbilical Cord Blood [UCB] Transplantation (ASH 2021, Dec 11-14. Abstract 333)
    • The objective of this study is to report the efficacy of HSCT with omidubicel as compared to standard umbilical cord blood transplantation in patients with hematologic malignancies.
    • The limitations of cord blood transplantation are delayed hematopoietic and immune recovery and increased transplant-related mortality, although a robust recovery of NK [natural killer] cells is evident.
    • Omidubicel is an advanced cell therapy for allogeneic HSCT that preserves stem cell function to optimize homing, engraftment, and differentiation.
    • Conclusions:
      • HSCT with omidubicel results in rapid hematopoietic recovery, reduced rates of infections, and no increase in GvHD [graft-versus-host disease] rates compared with standard UCB transplantation.
      • In the immediate post-transplant period, immune cell recovery was significantly faster with omidubicel compared with standard UCB transplantation despite receiving a lower number of T cells at transplant.
      • Enhanced recovery of circulatory mDC [myeloid dendritic cells], pDC [plasmacytoid dendritic cells], NK, and CD4+ T cells within the first 28 days, and sustained B-cell recovery from Day 28 through the first year, were observed.
      • These results demonstrate rapid and functional reconstitution of T- and B-cell subsets following transplant with omidubicel, which provides mechanistic support for the lower rates of severe infection observed in the omidubicel-treated patients.
Recent Videos
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Sarah Larson, MD, the medical director of the Immune Effector Cell Therapy Program in the Division of Hematology/Oncology at David Geffen School of Medicine at University of California, Los Angeles (UCLA)
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Ben Samelson-Jones, MD, PhD, assistant professor pediatric hematology, Perelman School of Medicine, University of Pennsylvania and Associate Director, Clinical In Vivo Gene Therapy, Children’s Hospital of Philadelphia
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Steven W. Pipe, MD, a professor of pediatric hematology/oncology at CS Mott Children’s Hospital
Haydar Frangoul, MD, the medical director of pediatric hematology/oncology at Sarah Cannon Research Institute and Pediatric Transplant and Cellular Therapy Program at TriStar Centennial
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Related Content
© 2025 MJH Life Sciences

All rights reserved.